AzTrials
AzTrials

WellbeingPROMOTENCT06566157

PROMOTE: The Effect of a Six Week Prebiotic Supplementation on Wellbeing of Young Adults.

A study testing Prebiotic and Maltodextrin (Corn) in people with Wellbeing and Healthy, run by University of Southampton at 1 site in United Kingdom.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The study will investigate whether taking a prebiotic for six weeks helps to reduce morning cortisol levels in healthy young adults with mild to moderate stress compared to a placebo. Individuals should continue with their usual lifestyle during the study. Other factors of wellbeing will also be assessed. Read more about this study

Who is it for?
Ages 18 to 25 yearsHealthy volunteers can take part
Conditions the study is for
Wellbeing, Healthy, Mental Health
What is being tested?
Prebiotic and Maltodextrin (Corn)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited Kingdom
Study dates
6 Jan 2025to 16 Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 25 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Aged 18-25 at time of recruitment
  • Body Mass Index (18.5 - 29.9 kg) : Healthy - Overweight
  • Stress score of 15≤ - ≥25 (DASS)
  • Willing and with capacity to give informed consent to participate at time of recruitment
  • Speak and comprehend English to a good standard
  • In good general health
  • Willing to provide stool, urine and blood (8mL) sample during intervention
  • Willing to attend 4 visits to Southampton General Hospital Clinical Research Facility over 10-11 weeks

Who cannot join

  • Consuming ≥ 14 units of alcohol/week (6 x 175 mL of wine, 6 pints of 4% beer)
  • Learning or behavioural difficulties (assessed on individual basis)
  • Planning a pregnancy in the next 6 months, pregnant, lactating or had a recent birth ≥6 months
  • Currently smoking or using e-cigarette, vape
  • Vulnerable adults (with self reported sever or very severe stress score (DASS)
  • Unwilling to suspend existing probiotic / prebiotic supplementation (with additional 4 weeks washout) before starting study.
Show all 14Show fewer
  • Medical exclusions:
  • Actively involved in therapy or psychiatric intervention of a diagnosed mental health condition
  • Prescribed psychotropic medication (Antidepressants, Monoamine Oxidase Inhibitors (MAOI's), Antipsychotics, sleeping pills, mood stabilisers etc)
  • Allergic to milk, soy, corn, penicillin or fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPS)
  • Currently prescribed laxatives, enemas, anti-coagulants or painkillers
  • Existing medical condition: cancer, hepatobiliary surgery, diabetes or diagnosed gastrointestinal diseases (irritable bowel disease, ulcerative colitis)
  • Involved in a recent pharmacology/psychological intervention, last 6 months
  • Recent antibiotic prescription, last 6 months

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • NIHR Southampton Clinical Research Facility

    Southampton, Hampshire, SO16 6YD

Other trials in United Kingdom

About this study

Official title: PROMOTE: The Effect of Prebiotic Supplementation on Salivary Cortisol Awakening Response in Young Adults With Mild-To-Moderate Self-Reported Stress: A Double Blinded Parallel Randomised Controlled-Trial.

The study will investigate whether taking a prebiotic for six weeks helps to reduce morning cortisol levels in healthy young adults with mild to moderate stress compared to a placebo. Individuals should continue with their usual lifestyle during the study. Other factors of wellbeing will also be assessed.

Read the detailed description

PROMOTE is a double blinded parallel randomised controlled-trial investigating if prebiotic supplementation reduce awakening salivary cortisol response, reported as area under the curve compared to a maltodextrin placebo in healthy young adults with a mild-to-moderate self reported stress score. There will be a focus on biological secondary outcomes to better understand how supplementation may influence the microbiome using metabolomics and sequencing techniques. In addition to other measures of wellbeing captured by questionnaires and activity monitors.

Being tested
Prebiotic, Maltodextrin (Corn)
Keywords
Prebiotics, Gut microbiome, Microbiome, Metabolomics, Sequencing, Stress, Wellbeing
Medical subject headings
Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PrebioticDietary supplement

    Also called WellBiome®, WellBiome® - Mineral Enriched Prebiotic Fibre Complex, Inulin, XOS

    WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %

  • Maltodextrin (Corn)Dietary supplement

    Also called Maltodextrin Placebo

    Placebo

Study groups in NCT06566157
Study groupRoleWhat they receive
PrebioticExperimentalWellBiome® prebiotic complex Inulin 67%, Xylooligosaccharides (XOS) 27%, Magnesium Chloride (MgCl2) 9.8 %
Receives: Dietary Supplement: Prebiotic
MaltodextrinPlacebo comparatorMaltodextrin (Corn origin)
Receives: Dietary Supplement: Maltodextrin (Corn)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Salivary Cortisol Awakening Response - Biological salivary cortisol (µg/dL)

    Salivary Cortisol Awakening Response (µg/dL) Measured on awakening and hereafter at 0, 15 , 30, 45 minutes Quantified by ELISA and presented as area under the curve, for each timepoint.

    Example outcome: 'Awakening salivary cortisol response was significantly lower in the prebiotic group compared to the placebo mean difference: -2.27( 95CI-3.68, -0.87) group after 6 weeks of supplementation.' [result sourced from clinicaltrials.gov NCT0521254]

    Measured: 6 collections across two working mornings per timepoint. (2 'baseline' - week 0 before supplementation; 2 'endpoint' - week 6 of supplementation ; 2 'follow-up' - within 3rd week (week 9) of supplement end)

Secondary outcomes (10)
  1. Good Sleeper Scale -15 items (GSS -15) self-reported sleep.

    GSS-15 - Manners, J et al (2023) questionnaire A 15 item questionnaire validated in a population of Australian adults to give a self-reported indices of sleep on a scale of confidence of being a good sleeper.

    10.1111/jsr.13717

    GSS-15 ≥ 45: High confidence of being a Good Sleeper GSS-15 40 - 44: Moderate confidence of being a Good Sleeper GSS-15 < 40: Low confidence of being a Good Sleeper

    Example outcome: 'There was no difference in the mean reported good sleeper score (43.25 43.25 (95% CI: -40.1, 46.2) of the prebiotic and placebo groups after 6 weeks of supplementation.'

    Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley

  2. Depression Anxiety and Stress Scales 42-items (DASS-42) questionnaire. Wellbeing and subjective mental health assessment.

    Depression, Anxiety and Stress Scales Lovibond, P. F., \& Lovibond, S. H. (1995) 10.1016/0005-7967(94)00075-u

    Scale Scores:

    DASS (42) Scores are calculated for each subset of the survey with the scale as follows where lower scores indicate a better outcome, while higher scores indicate worse results:

    Depression Anxiety Stress Normal 0-9 0-7 0-14 Mild 10-13 8-9 15-18 Moderate 14-20 10-14 19-25 Severe 21-27 15-19 26-33 Extremely Severe 28+ 20+ 34+

    Example outcome: 'There was a significant reduction in the stress score observed in the prebiotic group (mean: -3.25 (p=0.004) after 6 weeks of supplementation when compared to the placebo group.'

    Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley

  3. Faceal microbial sequencing and interventional group microbiota compositional change

    16S ribosomal ribonucleic acid (rRNA) sequencing of stool samples measuring microbial composition change.

    Units: Read counts, Operational Taxanomic Units (OTUs) and Relative abundance provide quantifications of the amount of bacterial genetic sequence present in a stool sample building an approximation of the faecal microbial composition to at least the genus level.

    Results are typical reported in compositional scores like alpha and beta diversity.

    Bray-Curtis dissimilarity is a scale of similarity where values closer to 1 are more distinct, while values close to 0 represent similar compositions.

    Example outcome: 'The beta diversity (a measure of compositional change) of the prebiotic group using Bray-Curtis dissimilarity increased by 22.7%, suggesting a compositional change from the placebo group.'

    Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).

  4. Short Food Frequency Questionnaire (SFFQ): Diet quality score

    Validated SFFQ for adults in the United Kingdom (UK) Cleghorn, CL. et al (2017) - University of Leeds

    Scores per subgroup (Fruit, Vegetables, Oily Fish, Fat and Non-Milk Extrinsic Sugars (NMEs)) are converted to scores ranging from 1-3 based on consumption. Lower scores indicating less intake, while scores of 3 indicate high intake of particular food groups (except for fats and NMEs which is reverse scaled - lower score matching closer to nutritional guideline).

    A final dietary quality score score is calculated from all subgroups with higher scores indicating better dietary quality.

    Example outcome: 'Dietary quality scores did not significantly differ among the prebiotic and placebo groups after 6 weeks. This indicates that participants' dietary habits remained consistent throughout the intervention, thereby minimizing dietary intake as a confounding factor in the comparison of the interventional groups.'

    Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley

  5. Activity monitoring using activewear devices

    Subsample analysis of biometric activity and sleep using FitBit Inspire 3.0. The Fitbit Inspire 2.0 can capture more objective measures of sleep including time spent in REM sleep phases, sleep duration, awakening and sleep latency.

    Example outcome: 'Sleep latency, defined as the time taken to fall asleep, was significantly reduced by 5.5 minutes (p < 0.05) after 6 weeks of prebiotic supplementation compared to the placebo group.'

    Measured: Continuous / 3 nights per 14 days (2 weeknights, 1 weekend night) depending on participants preference.

  6. Urine Metabolomics (Untargeted)

    Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of urine samples.

    NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.

    Example outcome: 'After 6 weeks of prebiotic supplementation, we observed significant increases in the urinary levels of dimethylglycine, indole-3-sulfate, and hippurate compared to the placebo group. These findings suggest that prebiotic supplementation may influence various metabolic pathways and gut microbiota activity.'

    Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).

  7. Faeces Metabolomics (Untargeted)

    Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of faeces.

    NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.

    Example outcome: 'After 6 weeks of prebiotic supplementation, we observed significant increases in the faecal levels of alanine and glutamate compared to the placebo group.

    More targeted approaches would be needed to quantify and determine if these amino acids are from dietary, human or microbiome origins like Liquid Chromatography Mass Spectrometry LC-MS).'

    Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).

  8. Plasma Metabolomics (Untargeted)

    Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of plasma samples.

    NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.

    Example outcome: 'After 6 weeks, prebiotic supplementation significantly increased faecal levels of alanine and glutamate compared to placebo, while lysine levels remained unchanged. Further targeted analyses, such as LC-MS, are needed to determine the origins and concentrations of these amino acids'.

    Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley

  9. Anthropometrics - Body composition

    Height (cm), Weight (Kg), Waist Circumference (cm) and Body Mass Index (BMI (kg/m2)

    Example outcome: 'Mean waist circumference (cm) did not differ significantly (p > 0.05) between the prebiotic and placebo groups after 6 weeks, suggesting that the prebiotic had no effect on body composition in terms of waist circumference.'

    Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley

  10. Adverse effects monitoring

    Monitoring or reporting of any adverse or severe adverse effects experienced during intervention.

    Reported and logged in active survey responses / contacting the study team directly

    Example outcome: 'There were two minor side effects reported early in the prebiotic supplementation, both instances self resolved within a few days and may be an effect of the initial introduction of a supplement to the individuals digestive system. No severe adverse effects were reported in either the prebiotic or the placebo control groups.'

    Measured: Continuous monitoring from start to end of study for all participants

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2024
  2. Study start6 Jan 2025 (estimated)
  3. Primary completion16 Sep 2025 (estimated)
  4. Study completion16 Sep 2026 (estimated)

Why it stopped: Funding partners dissolved prior to study launch

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blind, Placebo, Randomised
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06566157
Sponsor's protocol ID
340693
Other IDs
89554
Acronym
PROMOTE
Status last verified
Dec 2024
First submitted
7 Aug 2024
Last updated
13 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will be anonymised and submitted to open access repositories upon the consent and permission of the participants. Biological data will not be available for secondary analysis but raw exports of biological data in anonymous form can be made available on conditional request provided ethics approval from a suitable institution is met.

Publications

  • Caspani G, Swann J. Small talk: microbial metabolites involved in the signaling from microbiota to brain. Curr Opin Pharmacol. 2019 Oct;48:99-106. doi: 10.1016/j.coph.2019.08.001. Epub 2019 Sep 14.

    PubMed 31525562

Questions about this trial

What is this clinical trial studying?

A study testing Prebiotic and Maltodextrin (Corn) in people with Wellbeing and Healthy, run by University of Southampton at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Salivary Cortisol Awakening Response - Biological salivary cortisol (µg/dL) (time frame: 6 collections across two working mornings per timepoint. (2 'baseline' - week 0 before supplementation; 2 'endpoint' - week 6 of supplementation ; 2 'follow-up' - within 3rd week (week 9) of supplement end)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06566157, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in